tiprankstipranks
Advertisement
Advertisement

HK:2509 Stock Latest News

Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
Company AnnouncementsQyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
1d ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
18d ago
2509
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
PremiumCompany Announcements
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
29d ago
2509
Qyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
PremiumCompany Announcements
Qyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
1M ago
2509
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
PremiumCompany Announcements
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
1M ago
2509
Qyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
PremiumCompany AnnouncementsQyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
2M ago
2509
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
Premium
Company Announcements
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
2M ago
2509
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
Premium
Company Announcements
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
3M ago
2509
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
PremiumCompany Announcements
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
3M ago
2509
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
3M ago
2509
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
3M ago
2509
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
3M ago
2509
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
PremiumCompany AnnouncementsQyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
3M ago
2509
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Premium
Company Announcements
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
3M ago
2509
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
Premium
Company Announcements
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
4M ago
2509
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
5M ago
2509
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
PremiumCompany Announcements
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
5M ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
6M ago
2509
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
PremiumCompany Announcements
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
6M ago
2509
Qyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
PremiumCompany AnnouncementsQyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
6M ago
2509
Qyuns Therapeutics Advances Global Clinical Trials with Key Approval
Premium
Company Announcements
Qyuns Therapeutics Advances Global Clinical Trials with Key Approval
7M ago
2509
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
Premium
Company Announcements
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
7M ago
2509

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >